Logo image of AXGN

AXOGEN INC (AXGN) Stock Fundamental Analysis

NASDAQ:AXGN - Nasdaq - US05463X1063 - Common Stock - Currency: USD

13.37  +0.16 (+1.21%)

Premarket: 13.76 +0.39 (+2.92%)

Fundamental Rating

4

Taking everything into account, AXGN scores 4 out of 10 in our fundamental rating. AXGN was compared to 187 industry peers in the Health Care Equipment & Supplies industry. While AXGN seems to be doing ok healthwise, there are quite some concerns on its profitability. AXGN has a decent growth rate and is not valued too expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

AXGN had positive earnings in the past year.
AXGN had a positive operating cash flow in the past year.
AXGN had negative earnings in each of the past 5 years.
In the past 5 years AXGN reported 4 times negative operating cash flow.
AXGN Yearly Net Income VS EBIT VS OCF VS FCFAXGN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M -40M

1.2 Ratios

AXGN has a better Return On Assets (-3.65%) than 67.38% of its industry peers.
AXGN's Return On Equity of -6.80% is fine compared to the rest of the industry. AXGN outperforms 70.05% of its industry peers.
Industry RankSector Rank
ROA -3.65%
ROE -6.8%
ROIC N/A
ROA(3y)-10.24%
ROA(5y)-11.1%
ROE(3y)-20.3%
ROE(5y)-20.84%
ROIC(3y)N/A
ROIC(5y)N/A
AXGN Yearly ROA, ROE, ROICAXGN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

With an excellent Gross Margin value of 74.18%, AXGN belongs to the best of the industry, outperforming 86.63% of the companies in the same industry.
AXGN's Gross Margin has been stable in the last couple of years.
AXGN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 74.18%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.72%
GM growth 5Y-1.5%
AXGN Yearly Profit, Operating, Gross MarginsAXGN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 60 80

More info and screens

5

2. Health

2.1 Basic Checks

AXGN does not have a ROIC to compare to the WACC, probably because it is not profitable.
AXGN has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, AXGN has more shares outstanding
The debt/assets ratio for AXGN has been reduced compared to a year ago.
AXGN Yearly Shares OutstandingAXGN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
AXGN Yearly Total Debt VS Total AssetsAXGN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

An Altman-Z score of 3.34 indicates that AXGN is not in any danger for bankruptcy at the moment.
AXGN's Altman-Z score of 3.34 is fine compared to the rest of the industry. AXGN outperforms 70.05% of its industry peers.
A Debt/Equity ratio of 0.45 indicates that AXGN is not too dependend on debt financing.
The Debt to Equity ratio of AXGN (0.45) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.45
Debt/FCF N/A
Altman-Z 3.34
ROIC/WACCN/A
WACC9.27%
AXGN Yearly LT Debt VS Equity VS FCFAXGN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

A Current Ratio of 4.28 indicates that AXGN has no problem at all paying its short term obligations.
The Current ratio of AXGN (4.28) is better than 67.38% of its industry peers.
A Quick Ratio of 2.65 indicates that AXGN has no problem at all paying its short term obligations.
AXGN has a Quick ratio of 2.65. This is comparable to the rest of the industry: AXGN outperforms 59.89% of its industry peers.
Industry RankSector Rank
Current Ratio 4.28
Quick Ratio 2.65
AXGN Yearly Current Assets VS Current LiabilitesAXGN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 221.43% over the past year.
Looking at the last year, AXGN shows a quite strong growth in Revenue. The Revenue has grown by 18.81% in the last year.
AXGN shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 11.92% yearly.
EPS 1Y (TTM)221.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%66.67%
Revenue 1Y (TTM)18.81%
Revenue growth 3Y13.72%
Revenue growth 5Y11.92%
Sales Q2Q%17.36%

3.2 Future

AXGN is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 45.46% yearly.
The Revenue is expected to grow by 15.96% on average over the next years. This is quite good.
EPS Next Y63.46%
EPS Next 2Y93.05%
EPS Next 3Y87.49%
EPS Next 5Y45.46%
Revenue Next Year16.08%
Revenue Next 2Y16.17%
Revenue Next 3Y14.14%
Revenue Next 5Y15.96%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
AXGN Yearly Revenue VS EstimatesAXGN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M
AXGN Yearly EPS VS EstimatesAXGN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 0.5 -0.5

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

AXGN is valuated quite expensively with a Price/Earnings ratio of 78.65.
Based on the Price/Earnings ratio, AXGN is valued a bit cheaper than 65.78% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 28.05. AXGN is valued rather expensively when compared to this.
The Price/Forward Earnings ratio is 27.60, which means the current valuation is very expensive for AXGN.
73.26% of the companies in the same industry are more expensive than AXGN, based on the Price/Forward Earnings ratio.
Compared to an average S&P500 Price/Forward Earnings ratio of 37.67, AXGN is valued a bit cheaper.
Industry RankSector Rank
PE 78.65
Fwd PE 27.6
AXGN Price Earnings VS Forward Price EarningsAXGN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, AXGN is valued a bit cheaper than 63.10% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 84.82
AXGN Per share dataAXGN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3 4

4.3 Compensation for Growth

The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
AXGN's earnings are expected to grow with 87.49% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.24
PEG (5Y)N/A
EPS Next 2Y93.05%
EPS Next 3Y87.49%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for AXGN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AXOGEN INC

NASDAQ:AXGN (7/25/2025, 8:00:01 PM)

Premarket: 13.76 +0.39 (+2.92%)

13.37

+0.16 (+1.21%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-08 2025-05-08/bmo
Earnings (Next)08-05 2025-08-05/bmo
Inst Owners86.36%
Inst Owner Change0.43%
Ins Owners0.95%
Ins Owner Change-0.03%
Market Cap608.87M
Analysts84.29
Price Target24.74 (85.04%)
Short Float %6.21%
Short Ratio3.6
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-54.04%
Min EPS beat(2)-222.55%
Max EPS beat(2)114.46%
EPS beat(4)3
Avg EPS beat(4)308.39%
Min EPS beat(4)-222.55%
Max EPS beat(4)1125.49%
EPS beat(8)7
Avg EPS beat(8)184.9%
EPS beat(12)11
Avg EPS beat(12)144.75%
EPS beat(16)14
Avg EPS beat(16)113.52%
Revenue beat(2)0
Avg Revenue beat(2)-0.88%
Min Revenue beat(2)-1.48%
Max Revenue beat(2)-0.28%
Revenue beat(4)2
Avg Revenue beat(4)1.96%
Min Revenue beat(4)-1.48%
Max Revenue beat(4)8.25%
Revenue beat(8)4
Avg Revenue beat(8)0.16%
Revenue beat(12)6
Avg Revenue beat(12)0.06%
Revenue beat(16)7
Avg Revenue beat(16)-0.74%
PT rev (1m)0%
PT rev (3m)-7.18%
EPS NQ rev (1m)5.55%
EPS NQ rev (3m)-18.81%
EPS NY rev (1m)0%
EPS NY rev (3m)-25.6%
Revenue NQ rev (1m)-0.86%
Revenue NQ rev (3m)-1.65%
Revenue NY rev (1m)-0.19%
Revenue NY rev (3m)-0.2%
Valuation
Industry RankSector Rank
PE 78.65
Fwd PE 27.6
P/S 3.13
P/FCF N/A
P/OCF 168.1
P/B 5.78
P/tB 6.12
EV/EBITDA 84.82
EPS(TTM)0.17
EY1.27%
EPS(NY)0.48
Fwd EY3.62%
FCF(TTM)0
FCFYN/A
OCF(TTM)0.08
OCFY0.59%
SpS4.27
BVpS2.31
TBVpS2.18
PEG (NY)1.24
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -3.65%
ROE -6.8%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 74.18%
FCFM N/A
ROA(3y)-10.24%
ROA(5y)-11.1%
ROE(3y)-20.3%
ROE(5y)-20.84%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.72%
GM growth 5Y-1.5%
F-Score6
Asset Turnover0.99
Health
Industry RankSector Rank
Debt/Equity 0.45
Debt/FCF N/A
Debt/EBITDA 6.42
Cap/Depr 49.14%
Cap/Sales 1.98%
Interest Coverage N/A
Cash Conversion 48.72%
Profit Quality N/A
Current Ratio 4.28
Quick Ratio 2.65
Altman-Z 3.34
F-Score6
WACC9.27%
ROIC/WACCN/A
Cap/Depr(3y)337.29%
Cap/Depr(5y)669.18%
Cap/Sales(3y)9.04%
Cap/Sales(5y)13.91%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)221.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%66.67%
EPS Next Y63.46%
EPS Next 2Y93.05%
EPS Next 3Y87.49%
EPS Next 5Y45.46%
Revenue 1Y (TTM)18.81%
Revenue growth 3Y13.72%
Revenue growth 5Y11.92%
Sales Q2Q%17.36%
Revenue Next Year16.08%
Revenue Next 2Y16.17%
Revenue Next 3Y14.14%
Revenue Next 5Y15.96%
EBIT growth 1Y97.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year1538.76%
EBIT Next 3Y212.61%
EBIT Next 5YN/A
FCF growth 1Y99.32%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y129.12%
OCF growth 3YN/A
OCF growth 5YN/A